Cargando…

Health System Capacity and Access Barriers to Diagnosis and Treatment of CVD and Diabetes in Nepal

BACKGROUND: Universal access to essential medicines and routine diagnostics is required to combat the growing burden of cardiovascular disease (CVD) and diabetes. Evaluating health systems and various access dimensions availability, affordability, accessibility, acceptability, and quality is crucial...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Abhishek, Kaplan, Warren A., Satheesh, Gautam, Poudyal, Indra Prasad, Gyawali, Pawan, Neupane, Dinesh, Bhandari, Parash Mani, Malla, Milan, Sapkota, Surendra, Mishra, Shiva Raj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ubiquity Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139299/
https://www.ncbi.nlm.nih.gov/pubmed/34040951
http://dx.doi.org/10.5334/gh.927
_version_ 1783695979844730880
author Sharma, Abhishek
Kaplan, Warren A.
Satheesh, Gautam
Poudyal, Indra Prasad
Gyawali, Pawan
Neupane, Dinesh
Bhandari, Parash Mani
Malla, Milan
Sapkota, Surendra
Mishra, Shiva Raj
author_facet Sharma, Abhishek
Kaplan, Warren A.
Satheesh, Gautam
Poudyal, Indra Prasad
Gyawali, Pawan
Neupane, Dinesh
Bhandari, Parash Mani
Malla, Milan
Sapkota, Surendra
Mishra, Shiva Raj
author_sort Sharma, Abhishek
collection PubMed
description BACKGROUND: Universal access to essential medicines and routine diagnostics is required to combat the growing burden of cardiovascular disease (CVD) and diabetes. Evaluating health systems and various access dimensions availability, affordability, accessibility, acceptability, and quality is crucial yet rarely performed, especially in low- and middle-income countries. OBJECTIVE: To evaluate health system capacity and barriers in accessing diagnostics and essential medicines for CVD and diabetes in Nepal. METHODS: We conducted a WHO/HAI nationally-representative survey in 45 health-facilities (public-sector: 11; private-sector: 34) in Nepal to collect availability and price data for 21 essential medicines for treating CVD and diabetes, during MayJuly 2017. Data for 13 routine diagnostics was obtained in 12 health facilities. Medicines were considered unaffordable if the lowest paid worker spends >1 days wage to purchase a monthly supply. To evaluate accessibility, we conducted facility exit interviews among 636 CVD patients. Accessibility (e.g., private-public health facility mix, travel to hospital/pharmacy) and acceptability (i.e. Nepals adoption of WHO Essential Medicine List, and patient medication adherence) were summarized using descriptive statistics, and we conducted a systematic review of relevant literature. We did not evaluate medicine quality. RESULTS: We found that mean availability of generic medicines is low (<50%) in both public and private sectors, and less than one-third medicines met WHOs availability target (80%). Mean (SD) availability of diagnostics was 73.1% (26.8%). Essential medicines appear locally unaffordable. On average, the lowest-paid worker would spend 1.03 (public-sector) and 1.26 (private-sector) days wages to purchase a monthly supply. For a person undergoing CVD secondary preventive-interventions in the private sector, the associated expenditure would be 7.511.2% of monthly household income. Exit-interviews suggest that a long/expensive commute to health-facilities and poor medicine affordability constrain access. CONCLUSIONS: This study highlights critical gaps in Nepals health system capacity to offer basic health services to CVD and diabetes patients, owing to low availability, poor affordability and accessibility of essential medicines and diagnostics. Research and policy initiatives are needed to ensure uninterrupted supply of affordable essential medicines and diagnostics.
format Online
Article
Text
id pubmed-8139299
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Ubiquity Press
record_format MEDLINE/PubMed
spelling pubmed-81392992021-05-25 Health System Capacity and Access Barriers to Diagnosis and Treatment of CVD and Diabetes in Nepal Sharma, Abhishek Kaplan, Warren A. Satheesh, Gautam Poudyal, Indra Prasad Gyawali, Pawan Neupane, Dinesh Bhandari, Parash Mani Malla, Milan Sapkota, Surendra Mishra, Shiva Raj Glob Heart Original Research BACKGROUND: Universal access to essential medicines and routine diagnostics is required to combat the growing burden of cardiovascular disease (CVD) and diabetes. Evaluating health systems and various access dimensions availability, affordability, accessibility, acceptability, and quality is crucial yet rarely performed, especially in low- and middle-income countries. OBJECTIVE: To evaluate health system capacity and barriers in accessing diagnostics and essential medicines for CVD and diabetes in Nepal. METHODS: We conducted a WHO/HAI nationally-representative survey in 45 health-facilities (public-sector: 11; private-sector: 34) in Nepal to collect availability and price data for 21 essential medicines for treating CVD and diabetes, during MayJuly 2017. Data for 13 routine diagnostics was obtained in 12 health facilities. Medicines were considered unaffordable if the lowest paid worker spends >1 days wage to purchase a monthly supply. To evaluate accessibility, we conducted facility exit interviews among 636 CVD patients. Accessibility (e.g., private-public health facility mix, travel to hospital/pharmacy) and acceptability (i.e. Nepals adoption of WHO Essential Medicine List, and patient medication adherence) were summarized using descriptive statistics, and we conducted a systematic review of relevant literature. We did not evaluate medicine quality. RESULTS: We found that mean availability of generic medicines is low (<50%) in both public and private sectors, and less than one-third medicines met WHOs availability target (80%). Mean (SD) availability of diagnostics was 73.1% (26.8%). Essential medicines appear locally unaffordable. On average, the lowest-paid worker would spend 1.03 (public-sector) and 1.26 (private-sector) days wages to purchase a monthly supply. For a person undergoing CVD secondary preventive-interventions in the private sector, the associated expenditure would be 7.511.2% of monthly household income. Exit-interviews suggest that a long/expensive commute to health-facilities and poor medicine affordability constrain access. CONCLUSIONS: This study highlights critical gaps in Nepals health system capacity to offer basic health services to CVD and diabetes patients, owing to low availability, poor affordability and accessibility of essential medicines and diagnostics. Research and policy initiatives are needed to ensure uninterrupted supply of affordable essential medicines and diagnostics. Ubiquity Press 2021-05-18 /pmc/articles/PMC8139299/ /pubmed/34040951 http://dx.doi.org/10.5334/gh.927 Text en Copyright: 2021 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Research
Sharma, Abhishek
Kaplan, Warren A.
Satheesh, Gautam
Poudyal, Indra Prasad
Gyawali, Pawan
Neupane, Dinesh
Bhandari, Parash Mani
Malla, Milan
Sapkota, Surendra
Mishra, Shiva Raj
Health System Capacity and Access Barriers to Diagnosis and Treatment of CVD and Diabetes in Nepal
title Health System Capacity and Access Barriers to Diagnosis and Treatment of CVD and Diabetes in Nepal
title_full Health System Capacity and Access Barriers to Diagnosis and Treatment of CVD and Diabetes in Nepal
title_fullStr Health System Capacity and Access Barriers to Diagnosis and Treatment of CVD and Diabetes in Nepal
title_full_unstemmed Health System Capacity and Access Barriers to Diagnosis and Treatment of CVD and Diabetes in Nepal
title_short Health System Capacity and Access Barriers to Diagnosis and Treatment of CVD and Diabetes in Nepal
title_sort health system capacity and access barriers to diagnosis and treatment of cvd and diabetes in nepal
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139299/
https://www.ncbi.nlm.nih.gov/pubmed/34040951
http://dx.doi.org/10.5334/gh.927
work_keys_str_mv AT sharmaabhishek healthsystemcapacityandaccessbarrierstodiagnosisandtreatmentofcvdanddiabetesinnepal
AT kaplanwarrena healthsystemcapacityandaccessbarrierstodiagnosisandtreatmentofcvdanddiabetesinnepal
AT satheeshgautam healthsystemcapacityandaccessbarrierstodiagnosisandtreatmentofcvdanddiabetesinnepal
AT poudyalindraprasad healthsystemcapacityandaccessbarrierstodiagnosisandtreatmentofcvdanddiabetesinnepal
AT gyawalipawan healthsystemcapacityandaccessbarrierstodiagnosisandtreatmentofcvdanddiabetesinnepal
AT neupanedinesh healthsystemcapacityandaccessbarrierstodiagnosisandtreatmentofcvdanddiabetesinnepal
AT bhandariparashmani healthsystemcapacityandaccessbarrierstodiagnosisandtreatmentofcvdanddiabetesinnepal
AT mallamilan healthsystemcapacityandaccessbarrierstodiagnosisandtreatmentofcvdanddiabetesinnepal
AT sapkotasurendra healthsystemcapacityandaccessbarrierstodiagnosisandtreatmentofcvdanddiabetesinnepal
AT mishrashivaraj healthsystemcapacityandaccessbarrierstodiagnosisandtreatmentofcvdanddiabetesinnepal